Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;36(5):1675-1691.
doi: 10.1111/jhn.13214. Epub 2023 Jul 28.

Nutritional management of people living with cystic fibrosis throughout life and disease continuum: Changing times, new challenges

Affiliations
Review

Nutritional management of people living with cystic fibrosis throughout life and disease continuum: Changing times, new challenges

Geneviève Mailhot et al. J Hum Nutr Diet. 2023 Oct.

Abstract

Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding for the ion channel cystic fibrosis transmembrane conductance regulator (CFTR). The management of CF disease has evolved in recent decades from treating downstream disease manifestations affecting the airways, the lungs and the gastrointestinal system to addressing the CFTR gene defect. The advent of CFTR modulators, which correct the functionality of the defective CFTR, contributes to reshaping the landscape of CF demographics, prognosis and therapies, including nutritional management. A spectrum of clinical manifestations is emerging within the same patient population where undernutrition and nutritional deficiencies coexist with excessive weight gain and metabolic derangements. Such contrasting presentations challenge current practices, require adjustments to traditional approaches, and involve more individualised interventions. This narrative review examines the current state of knowledge on the nutritional management of people living with cystic fibrosis from early life to adulthood in the era of CFTR modulation.

Keywords: CFTR modulators; cystic fibrosis; life stages; nutrition.

PubMed Disclaimer

References

REFERENCES

    1. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195-2211.
    1. Cystic Fibrosis Foundation. https://www.cff.org/managing-cf/cftr-modulator-therapies (2023). Accessed July 6 2023.
    1. Vertex Pharmaceuticals Incorporated. https://www.vrtx.com/medicines/our-approved-medicines/ (2023). Accessed July 6 2023.
    1. Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on cftr function in patients with cystic fibrosis and one or two F508del Alleles. Am J Respir Crit Care Med. 2022;205:540-549.
    1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. Bethesda, Maryland: Cystic Fibrosis Foundation; 2022.

MeSH terms

Substances